AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24050512 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA)
Number of subjects: 648
Study 21832979 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 80
Study 21832979 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 80
Study 19272686 — intervention group
Group type: EXPERIMENTAL
Intervention: C677T polymorphism (mutant TT genotype) in patients with ESRD
Number of subjects: 677
Study 19272686 — intervention group
Group type: EXPERIMENTAL
Intervention: C677T polymorphism (all patients)
Number of subjects: 677
Study 19272686 — intervention group
Group type: EXPERIMENTAL
Intervention: C677T polymorphism (patients with advanced CKD)
Number of subjects: 677
Study 19272686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant T allele at nucleotide 677 (patients with ESRD)
Number of subjects: 677
Study 19272686 — intervention group
Group type: EXPERIMENTAL
Intervention: A1298C polymorphism
Number of subjects: 677
Study 17355722 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototypical representatives under accountability
Number of subjects: 224
Study 17355722 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral representatives under accountability
Number of subjects: 224
Study 14697022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 89
Study 14697022 — intervention group
Group type: COMPARATOR
Intervention: Control (air treatment)
Number of subjects: 89
Study 11360072 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (2.5 ml of 0.5% bupivicaine)
Number of subjects: 65
Study 11360072 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml of 0.5% bupivicaine)
Number of subjects: 65
Study 9125675 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of acetazolamide with diuretic therapy
Number of subjects: 0
Study 9125675 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with hydrochlorothiazide or furosemide
Number of subjects: 0
Study 8150549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 0.5 g
Number of subjects: 5
Study 8150549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g
Number of subjects: 5
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-agonist terbutaline (5 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-agonist orciprenaline (10 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-antagonist acebutolol (200 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-antagonist metoprolol (50 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-antagonist propranolol (5 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1 + 2-antagonist with ISA pindolol (5 mg)
Number of subjects: 11
Study 2878632 — intervention group
Group type: COMPARATOR
Intervention: Beta 1-antagonists (acebutolol and metoprolol)
Number of subjects: 11
Study 31993916 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlabeled response options of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Number of subjects: 1437
Study 31993916 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard approach to scoring and scores obtained by collapsing adjacent response categories
Number of subjects: 1437
Study 31388755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian hyperstimulation‐IVF (COH‐IVF)
Number of subjects: 211
Study 31388755 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle‐IVF (MNC‐IVF)
Number of subjects: 211
Study 31388755 — intervention group
Group type: COMPARATOR
Intervention: Naturally conceived to subfertile couples (Sub‐NC)
Number of subjects: 211
Study 27035842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion 0.5 μg/kg/h throughout the surgery after a loading dose of 1 μg/kg over 10 minutes, continued at 0.2 μg/kg/h for 24 hours postoperatively
Number of subjects: 60
Study 27035842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 60
Study 27035842 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 60
Study 26154345 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + protein (whey 17 g + colostrum 3 g + leucine 2 g)
Number of subjects: 18
Study 26154345 — intervention group
Group type: COMPARATOR
Intervention: Resistance training + placebo
Number of subjects: 18
Study 24162943 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention (manual based coping intervention)
Number of subjects: 260
Study 24162943 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment alone
Number of subjects: 260
Study 21029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 50% of 1RM
Number of subjects: 24
Study 21029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 75% of 1RM
Number of subjects: 24
Study 21029329 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic knee extensions at 100% of 1RM
Number of subjects: 24
Study 19577081 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled normoxic cardiopulmonary bypass (50-0 mm Hg)
Number of subjects: 67
Study 17045959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple extinction group (videotapes of the same spider in three different locations)
Number of subjects: 0
Study 17045959 — intervention group
Group type: EXPERIMENTAL
Intervention: Single extinction group (videotaped spider in one specific location)
Number of subjects: 0
Study 17045959 — intervention group
Group type: COMPARATOR
Intervention: Control group (videotapes of the location without the spider)
Number of subjects: 0
Study 15123970 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 40
Study 15123970 — intervention group
Group type: COMPARATOR
Intervention: Standard NICU care (nontucking)
Number of subjects: 40
Study 11438317 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily per os)
Number of subjects: 70
Study 11438317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10097621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology-specific Quality of Life (DSQL) instrument
Number of subjects: 0
Study 10097621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8062311 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (once-daily theophylline) in No Time Lapse (NTL) group
Number of subjects: 10
Study 8062311 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (once-daily theophylline) in Time Lapse (TL) group
Number of subjects: 10
Study 2661612 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5, 10, 15, 20 mg
Number of subjects: 26
Study 2661612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31670530 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation‐based intervention (7 sessions)
Number of subjects: 0
Study 29753370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose irbesartan combined with spironolactone (group D)
Number of subjects: 244
Study 29753370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose irbesartan combined with spironolactone (group C)
Number of subjects: 244
Study 28645301 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sternal precautions
Number of subjects: 72
Study 28645301 — intervention group
Group type: COMPARATOR
Intervention: Standard sternal precautions
Number of subjects: 72
Study 26176163 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 733
Study 26176163 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 733
Study 23536690 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted tetravalent influenza vaccine
Number of subjects: 265
Study 23536690 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of tetravalent influenza vaccine
Number of subjects: 265
Study 23536690 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of MF59-adjuvanted A/H5N1 vaccine
Number of subjects: 265
Study 22235686 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills, 6 g tid for 12 weeks
Number of subjects: 310
Study 22235686 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills, 6 g bid for 12 weeks
Number of subjects: 310
Study 22235686 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills
Number of subjects: 310
Study 22235686 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills
Number of subjects: 310
Study 19826646 — intervention group
Group type: EXPERIMENTAL
Intervention: APC + AI
Number of subjects: 172
Study 19826646 — intervention group
Group type: COMPARATOR
Intervention: Hemoclips + AI
Number of subjects: 172
Study 17181378 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous PTH(1-84) 100 microg/day
Number of subjects: 2532
Study 17181378 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous PTH(1-84) 100 microg/day followed by alendronate 10 mg/day
Number of subjects: 2532
Study 17181378 — intervention group
Group type: COMPARATOR
Intervention: PTH(1-84) in combination with alendronate
Number of subjects: 2532
Study 15584815 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming with high cue validity
Number of subjects: 0
Study 15584815 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming with low cue validity
Number of subjects: 0
Study 15584815 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity with high cue validity
Number of subjects: 0
Study 15584815 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity with low cue validity
Number of subjects: 0
Study 11732460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration (DTP‐HBV‐Hib)
Number of subjects: 120
Study 11732460 — intervention group
Group type: COMPARATOR
Intervention: Separate administrations of DTP‐HBV and Hib vaccines
Number of subjects: 120
Study 9395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Enermed device (magnetically active), worn for 10-24 hours a day for 2 months.
Number of subjects: 30
Study 9395691 — intervention group
Group type: COMPARATOR
Intervention: Placebo Enermed device (magnetically inactive), worn for 10-24 hours a day for 2 months.
Number of subjects: 30
Study 7925202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 30
Study 7925202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study 3134739 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnyl (plain acetylsalicylic acid) 75 mg daily for 2 weeks
Number of subjects: 12
Study 3134739 — intervention group
Group type: EXPERIMENTAL
Intervention: Globentyl (micro-encapsulated acetylsalicylic acid) 75 mg daily for 2 weeks
Number of subjects: 12
Study 30739261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental injuries in females
Number of subjects: 100
Study 30739261 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown fracture of maxillary teeth
Number of subjects: 100
Study 30739261 — intervention group
Group type: EXPERIMENTAL
Intervention: Root fracture in maxillary incisors and canines
Number of subjects: 100
Study 30739261 — intervention group
Group type: EXPERIMENTAL
Intervention: Avulsion, extrusion, and luxation
Number of subjects: 100
Study 27148676 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg by mouth once daily, with a possible increase to 200 mg depending on response)
Number of subjects: 40
Study 27148676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27148676 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 40
Study 26192398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 546
Study 26192398 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ventilation (CV)
Number of subjects: 546
Study 26192398 — intervention group
Group type: COMPARATOR
Intervention: ENE status (nonenrollment)
Number of subjects: 546
Study 23277434 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLWI-T measurement
Number of subjects: 60
Study 23277434 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine administration
Number of subjects: 60
Study 23277434 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary capillary wedge pressures
Number of subjects: 60
Study 23277434 — intervention group
Group type: COMPARATOR
Intervention: Unsuitability for transplantation
Number of subjects: 60
Study 23277434 — intervention group
Group type: COMPARATOR
Intervention: Transplant survival
Number of subjects: 60
Study 23277434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravimetric analysis
Number of subjects: 60
Study 23277434 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between EVLW-T and EVLW-G
Number of subjects: 60
Study 23277434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in BAL fluid
Number of subjects: 60
Study 16998740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiography (DSE) with echo-contrast (Optisone) at 0-40 microg/kg
Number of subjects: 69
Study 16998740 — intervention group
Group type: EXPERIMENTAL
Intervention: DSE
Number of subjects: 69
Study 12709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide
Number of subjects: 0
Study 12709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline citrate
Number of subjects: 0
Study 12709088 — intervention group
Group type: EXPERIMENTAL
Intervention: General or specific dietary and drinking advice
Number of subjects: 0
Study 12709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 0
Study 9915315 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (30 microg/kg bolus administered progressively in 10 min, followed by a continuous infusion of 0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 22
Study 9915315 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 22
Study 9915315 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 22
Study 7675954 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.33 mg phenylpropanolamine gum
Number of subjects: 107
Study 7675954 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 107
Study 1665178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Number of subjects: 174
Study 1665178 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Number of subjects: 174
Study 7235321 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol metered dose aerosol (1.5 mg)
Number of subjects: 10
Study 7235321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31493958 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal statements of empathy
Number of subjects: 466
Study 31493958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal actions of empathy
Number of subjects: 466
Study 31493958 — intervention group
Group type: EXPERIMENTAL
Intervention: Context of medical appointment
Number of subjects: 466
Study 29902175 — intervention group
Group type: EXPERIMENTAL
Intervention: PA Barriers subscales
Number of subjects: 641
Study 29902175 — intervention group
Group type: EXPERIMENTAL
Intervention: PA Outcome Expectancies subscales
Number of subjects: 641
Study 29902175 — intervention group
Group type: EXPERIMENTAL
Intervention: PA Home Environment subscale on support for PA
Number of subjects: 641
Study 28807986 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine-driven ventilator
Number of subjects: 24
Study 28807986 — intervention group
Group type: COMPARATOR
Intervention: Self-inflating bag
Number of subjects: 24
Study 25056444 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo expectation group (told the cream would reduce pain)
Number of subjects: 134
Study 25056444 — intervention group
Group type: COMPARATOR
Intervention: No-expectation group (told the cream was a hand cleanser)
Number of subjects: 134
Study 25056444 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prior experience with pain from cold water immersion
Number of subjects: 134
Study 23436265 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid for 8 days
Number of subjects: 16
Study 23436265 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg bid for 16 days with etravirine 200 mg bid on days 9-16
Number of subjects: 16
Study 23436265 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of etravirine and lopinavir/ritonavir
Number of subjects: 16
Study 21045816 — intervention group
Group type: EXPERIMENTAL
Intervention: EST followed by large balloon dilation (LBD)
Number of subjects: 90
Study 21045816 — intervention group
Group type: COMPARATOR
Intervention: EST followed by mechanical lithotripsy (ML)
Number of subjects: 90
Study 18328834 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 267
Study 18328834 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Kinase (CK)
Number of subjects: 267
Study 18328834 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Kinase-MB (CK-MB)
Number of subjects: 267
Study 18328834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 267
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: RecImMir (hand laterality recognition, imagined movements, mirror movements)
Number of subjects: 20
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: ImRecIm (imagined movements, recognition, imagined movements)
Number of subjects: 20
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: RecMirRec (recognition, mirror movements, recognition)
Number of subjects: 20
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand laterality recognition (across all groups)
Number of subjects: 20
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements (following hand laterality recognition)
Number of subjects: 20
Study 15733631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movements (following imagined movements)
Number of subjects: 20
Study 14508310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 45
Study 14508310 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐Line ARX index (AAI)
Number of subjects: 45
Study 14508310 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted propofol effect‐site concentration (CePROP)
Number of subjects: 45
Study 14508310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined information from CePROP, CeREMI, and BIS or AAI
Number of subjects: 45
Study 14508310 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent variables (BIS, AAI, CePROP)
Number of subjects: 45
Study 14508310 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 45
Study 10647274 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 10647274 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological therapeutic modalities (radiofrequency catheter ablation, implantable antiarrhythmic devices)
Number of subjects: 0
Study 10647274 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic practice modifications
Number of subjects: 0
Study 9084513 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually controlled infusion of propofol (10‐12 mg/kg/h) and alfentanil (25 micrograms/kg/h) for 2 min, followed by atracurium (5 mg) and propofol (1‐1.5 mg/kg) as a bolus induction dose over 20 s.
Number of subjects: 60
Study 9084513 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal (4‐5 mg/kg) and fentanyl (2 micrograms/kg), atracurium (5 mg) and succinylcholine (1.5 mg/kg).
Number of subjects: 60
Study 9084513 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal (4‐5 mg/kg) with additional sublingual nifedipine (1/2 capsule) 10 min prior to induction.
Number of subjects: 60
Study 1879184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin (500 or 750 mg every 12 hours)
Number of subjects: 102
Study 1879184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin
Number of subjects: 102
Study 1879184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular imipenem/cilastatin (500 mg)
Number of subjects: 102
Study 6978144 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35, 868 (diisopropyl phenol in cremophor)
Number of subjects: 0
Study 6978144 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study 30672140 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-SIB (salbutamol and ipratropium by MDI with valved-holding chamber and mask)
Number of subjects: 103
Study 30672140 — intervention group
Group type: COMPARATOR
Intervention: NEB-SIB (salbutamol and ipratropium by nebulizer)
Number of subjects: 103
Study 27979818 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure (n = 17)
Number of subjects: 59
Study 27979818 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure (n = 22)
Number of subjects: 59
Study 27979818 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n = 20)
Number of subjects: 59
Study 26021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 80
Study 26021224 — intervention group
Group type: COMPARATOR
Intervention: Repeated disconnection group
Number of subjects: 80
Study 24300843 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose sinogram-affirmed iterative reconstruction (HD-SAFIRE(2))
Number of subjects: 59
Study 24300843 — intervention group
Group type: COMPARATOR
Intervention: Full-dose filtered back projection images (FD-FBP)
Number of subjects: 59
Study 22074592 — intervention group
Group type: EXPERIMENTAL
Intervention: OHP (octenidine dihydrochloride/phenoxyethanol)
Number of subjects: 126
Study 22074592 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 126
Study 19139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based concurrent chemoradiotherapy
Number of subjects: 644